The Global Health Body Sounds Concern Over Severe Lack of Obesity Injections

Fewer than a tenth of individuals that would benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it issues its inaugural guidance on the medications.

With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer access to this class of drugs.

Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.

"Our new guidance recognises that obesity is a long-term condition that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are major hurdles to widespread access to the treatments that can assist patients in reducing significant weight, explains the body.

Weight-Loss Drug Shortage

Despite the present best projected case, the production of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, according to the WHO.

The guideline encourages governments and firms to increase availability, through measures including patent sharing.

A patent on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.

The Way Obesity Drugs Operate

These medications imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so users consume fewer calories.

Patients commonly see weight reduction in the initial weeks of commencing the regular doses.

Evidence indicates people may regain a significant portion within a year of stopping the treatment, when their usual food cravings resume.

Being carrying excess weight elevates your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight impacts people in all nations and was associated with 3.7 million fatalities worldwide in 2024, according to the health agency.